OTC (over-the-counter) diagnostics and mix/match hip implants under MHRA (Medicines & Healthcare Products Regulatory Agency) scrutiny
This article was originally published in Clinica
The UK's over-the-counter diagnostics market and the "general practice of mixing and matching hip replacement implants" contrary to manufacturers instructions are among the areas under closest scrutiny by the Medicines and Healthcare products Regulatory Agency (MHRA).
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
A recent Department of Health and Human Services proposal to review regulations every 10 years may mean good things for the device industry, said David Hoffmeister, partner, Wilson Sonsini Goodrich & Rosati.